28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018)

Piperacillin-tazobactam inferior to meropenem for E. coli, K. pneumoniae bloodstream infections

Roshini Claire Anthony, 20180522140700

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Seven-day antibiotic course as effective as 14-day for gram-negative bacteraemia

Roshini Claire Anthony, 20180515140700

Patients hospitalized with gram-negative bacteraemia have similar outcomes regardless of whether they receive a 7-day or 14-day course of antibiotic therapy, according to a study presented at ECCMID 2018.

Shorter antibiotic treatment may increase long-term cellulitis relapse risk

Roshini Claire Anthony, 20180514140700

While a 6-day course of flucloxacillin appeared as effective as a 12-day course in curing and reducing short-term risk of relapse among patients hospitalized for cellulitis, the 6-day course led to a greater risk of relapse at 90 days, according to a study from The Netherlands.